SUPPLEMENTARY DISCUSSION

Alternatively spliced isoforms of RPTPα found in normal cells
Two alternatively spliced mRNAs, differing in their 5' untranslated regions, are translated into the ubiquitously expressed 793 amino acid RPTPα isoform that is found in all the cancer cell types studied here. A third mRNA variant expresses RPTPα802, an isoform with a nineamino acid insertion in the extracellular domain, which is expressed in a few tissues such as brain and fat (Daum et al, 1994; Kaplan et al, 1990; Krueger et al, 1990; Matthews et al, 1990; Norris et al, 1997; Sap et al, 1990) . Tyr798 in RPTPα802 is homologous to Tyr789 in RPTPα; for clarity we to refer to this as Tyr798/789 in the discussion below.
Effect of Tyr789→Phe mutation in different biological systems
Care is required in interpreting experiments testing the effect of Y789F mutation, which is quantitative and biological-system dependent: Vacaru and den Hertog (2010a) analyzed overexpressed Src and RPTPα in Src/Yes/Fyn-deficient cells that were immortalized by SV40 large T antigen and showed that Y798/789F mutation of RPTPα or, conversely, SH2 mutation of Src, reduces but does not eliminate RPTPα-Src association (Fig. 7B , C of that paper). Thus, it is not surprising that some ability of RPTPα802(Y798/789F) to dephosphorylate Src can be detected when it is expressed at high levels by a retroviral vector (Kapp et al, 2007) . However, even in this case it does not transform NIH3T3 cells unless Src is also overexpressed (Kapp 2007) . Interestingly, wt RPTPα802 cannot be stably expressed in this system, consistent with the possibility that increased activity relative to RPTPα802(Y798/789F) renders it toxic (Lammers, 2000) .
Potential cellular roles of cryptic exon cx95
Cx95 it is flanked by excellent U2 splice signals ( Fig. 2A) , its 3' splice boundary is contained in a bioinformatic database of predicted splice junctions (Wang et al, 2008) , and the ExonScan algorithm (Wang et al, 2004) , which analyzes a sequence for 5' and 3' splice sites and the presence/absence of exonic splicing enhancer/silencer motifs, predicts that it is an internal exon (p = 0.001). In addition, the high conservation within placental mammals of cx95 and the even higher conservation of its flanking regions (Fig. 7) suggests that it is an alternatively spliced exon: As previously noted and verified in Fig. 7B , the flanking regions of alternatively spliced exons are generally more conserved than those of constitutive exons (Kaufmann et al, 2004; Sorek & Ast, 2003; Sugnet et al, 2006; Yeo et al, 2005) ; the flanking regions of cx95 are more conserved than most known alternatively spliced exons. Moreover, RankVista analysis (Frazer et al, 2004; Prabhakar et al, 2006; Wang et al, 2007 ; http://genome.lbl.gov/vista/index.shtml) identifies the 317 nt region which includes cx95 as an "extremely conserved region" (ECR; p=0.06). Visel et al. (2008) have reported that expression of roughly half of such ECRs enhanced reporter gene expression in various tissues of the developing mouse embryo, particularly in the central nervous system. Intriguingly, the primary defects observed in RPTPα-knockout mice involve brain and neuronal function (Kostic et al, 2007; Petrone et al, 2003; Skelton et al, 2003) , brain has the highest proportion of alternatively spliced genes (Yeo et al, 2004) , and brain expresses large amounts of a RPTPα splice variant having a small insertion in its extracellular domain (Kapp et al, 2007) .
This suggests that cx95 might normally function as an alternative exon in brain and/or other tissues, particularly during development. For example, RPTPα245 itself might be expressed to activate wt RPTPα in restricted tissue types and/or at special times. This could have escaped detection, particularly since many anti-RPTPα antibodies might not react with this truncated form. Indeed, a transcript [FLJ Human cDNA Database (http://flj.lifesciencedb.jp) FLJ33424; GenBank AK090743.1] in which cx95 is inserted exactly as in RPTPα245 has been found in a screen of full-length cDNAs from normal human brain (Ota et al, 2004) . (This transcript has additional splice variations that preclude translation of cx95, but it supports the existence of a normal mechanism for cx95 inclusion in an mRNA.)
A different possibility follows from the suggestion (Ni et al, 2007) that the inclusion of extremely conserved alternatively spliced stop-codon-exons such as cx95 is used to regulate expression of normal mRNAs by diverting pre-mRNAs to futile endpoints that are degraded by nonsense-mediated decay (NMD). Indeed, the RPTPα245 mRNA satisfies the prediction rule for NMD (Chang et al, 2007) and might normally be degraded. In that case its survival might result from changes in the tumor microenvironment such as hypoxia and amino acid deprivation that have been shown to inhibit NMD (Gardner; 2010). However, there is currently no direct in vivo evidence linking inhibition of NMD to tumor formation. , 1996) . (The left wedge-right cleft interaction is hidden on the back of the dimer.) Under normal conditions, the Grb2 SH2 domain is bound to RPTPα pTyr789 (den Hertog et al, 1994; Su et al, 1994 ) and its C-terminal SH3 domain is bound to RPTPα D1 by an interaction involving Arg469 (den Hertog & Hunter, 1996; Su et al, 1996) . The position of the N-terminal Grb2 SH3 domain (shown in gray) is unknown; it is located here according to the suggestion (den Hertog & Hunter, 1996) [based on the Grb2 crystal structure (Maignan et al, 1995) and the interference of RPTPα-Grb2 binding with SOS binding] that it is near the C-SH3. We hypothesize that the Grb2 SH2 domain binds to pTyr789 from one RPTPα monomer while the C-SH3 domain binds to D1 from the other monomer. While the drawing supposes that the dimer has the "head-to-head" conformation suggested by the RPTPα D1-dimer crystal structure (Bilwes et al, 1996) , the model is also consistent with the "head-to-toe" conformation suggested by analogy to the RPTPγ-dimer structure (Barr et al, 2009 ) and an analogous drawing can be made for that case. b, When RPTP245 displaces one RPTPα monomer, the binding of Grb2 to the bound RPTPα is weakened or eliminated because of the lack of a cross-binding site for C-SH3. The drawing assumes that RPTPα245 and RPTPα form a heterodimer analogous to the homodimer. However, the model only requires that RPTPα245 binding disrupts the RPTPα homodimer by any means. 
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